Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4d Pharma Plc Share News (DDDD)

Share Price Information for 4d Pharma Plc (DDDD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 125.00
Bid: 125.00
Ask: 126.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.80%)
Open: 121.50
High: 127.00
Low: 119.00
Yest. Close: 119.50
DDDD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

4D Pharma Gets Approval To Restart Thetanix Phase I Clinical Study

10 Jun 16 07:30

4D Pharma irritable bowel treatment proves safe in clinical trial

(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro

23 May 16 12:49

4d Pharma Says Blautix Treatment Meets Primary Endpoint In Trial

23 May 16 06:58

AGM, EGM Calendar - Week Ahead

17 May 16 15:11

AGM, EGM Calendar - Week Ahead

16 May 16 15:10

4D Pharma gobbles up Biomar production assets

(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc

8 Apr 16 16:17

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

8 Apr 16 08:25

4d Pharma Annual Loss Widens On Higher Research Spending

31 Mar 16 08:47

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

26 Feb 16 15:49

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

26 Feb 16 09:16

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

10 Feb 16 15:12

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

10 Feb 16 08:57

4d Pharma Gets Good Early Results From Blautix Trials

19 Jan 16 07:51

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

8 Dec 15 07:46

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

26 Nov 15 10:10

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.